TITLE

Pharmacogenetics and Clopidogrel Response in Patients Undergoing Percutaneous Coronary Interventions

AUTHOR(S)
Beitelshees, A. L.; Horenstein, R. B.; Vesely, M. R.; Mehra, M. R.; Shuldiner, A. R.
PUB. DATE
March 2011
SOURCE
Clinical Pharmacology & Therapeutics;Mar2011, Vol. 89 Issue 3, p455
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the association between cytochrome P450 2C19 (CYP2C19) and clopidogrel response in patients under percutaneous coronary interventions. It says that studies from 2008 show that CYP2C19*2 genotype increase the risk of patients to have cardiovascular events but the Platelet Inhibition and Patient Outcomes (PLATO) data reveal no relationship between outcomes and the ABCB1 genotype. It adds that physicians could continue using clopidogrel or use other antiplatelet agents.
ACCESSION #
58146000

 

Related Articles

  • Drug and Medical Device Interactions: Stent Thrombosis and Personalizing Clopidogrel Therapy. Giusti, Betti; Gori, Anna Maria; Marcucci, Rossella; Saracini, Claudia; Vestrini, Anna; Abbate, Rosanna // Current Pharmacogenomics & Personalized Medicine;2010, Vol. 8 Issue 2, p124 

    Antiplatelet therapy with aspirin and clopidogrel, aimed to inhibit platelet function and reactivity, is the recommended standard of care for reducing the occurrence of cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention with stent...

  • Clopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery Disease. Terpening, Chris // Clinical Medicine Insights: Cardiology;2010, Issue 4, p117 

    The thienopyridine antiplatelet agent clopidogrel is an effective drug for the prevention of vascular events. However, data has accumulated over time to suggest it is prone to significant interpatient variability. While there are several factors that contribute to this, one of the most important...

  • The role of genetic factors in clopidogrel antiplatelet therapy. Cieślewicz, Artur Robert; Kaźmierczak, Ewa; Jabłecka, Anna // Advances in Interventional Cardiology;2012, Vol. 8 Issue 2, p126 

    Thienopyridine derivative antiplatelet agents play an important role in the treatment of coronary artery disease. Clopidogrel is a drug blocking action of the platelet ADP receptor (P2Y12). It is applied in the form of a prodrug that requires metabolic activation by cytochrome P450 enzymes. The...

  • Monitoring Aspirin and Clopidogrel Response: Testing Controversies and Recommendations. Karathanos, Athanasios; Geisler, Tobias // Molecular Diagnosis & Therapy;Jun2013, Vol. 17 Issue 3, p123 

    Antiplatelet therapy is the cornerstone of the treatment for patients with coronary artery disease (CAD). Dual therapy with clopidogrel and aspirin is currently the standard treatment after percutaneous coronary interventions. However, despite the use of clopidogrel, a considerable number of...

  • The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin. Neergaard-Petersen, Søs; Hvas, Anne-Mette; Grove, Erik Lerkevang; Larsen, Sanne Bøjet; Gregersen, Søren; Kristensen, Steen Dalby // PLoS ONE;7/6/2015, Vol. 10 Issue 7, p1 

    Background: Hyperglycaemia may attenuate the antiplatelet effect of aspirin and thereby increase the risk of cardiovascular events. We investigated the influence of increased haemoglobin A1c (HbA1c) levels on platelet aggregation and turnover in a large cohort of patients with coronary artery...

  • SHORT CUTS. Fister, Kristina // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/5/2009, Vol. 339 Issue 7720, p536 

    This section discusses various health-related studies published in different journals. A study published in the "New England Journal of Medicine" estimated the cumulative doses of radiation received by patients in the U.S. during imaging procedures. Another study published in the same journal...

  • Effect of CYP2C19 variants on clopidogrel. Kuritzky, Louis // Primary Care Reports;Nov2009 Primary Care, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Effect of CYP2C19 variants on clopidogrel. Kuritzky, Louis // Neurology Alert;Nov2009 Primary Care, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Antiplatelet Effect of Clopidogrel Can Be Reduced by Calcium-Channel Blockers. Kwon-Duk Seo; Young Dae Kim; Young-Won Yoon; Jong-Youn Kim; Kyung-Yul Lee // Yonsei Medical Journal;May2014, Vol. 55 Issue 3, p683 

    Purpose: Clopidogrel is metabolized by the hepatic cytochrome P450 (CYP) system into its active thiol metabolite. CYP3A4 is involved in the metabolism of both clopidogrel and dihydropyridine calcium channel blockers (CCBs). A few reports have suggested an inhibitory interaction between CCBs and...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics